The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

1024 ET - Novo Nordisk's next-generation weight-loss drug amycretin has potential to become a blockbuster, Bernstein analysts say in a research note. The Danish drugmaker reported positive results from a mid-stage trial of the drug in diabetes patients, which showed weight loss of up to 14.5% at 36 weeks, the analysts say. If the drug can achieve weight loss greater than 20% in a late-stage trial with an attractive tolerance profile, then it has blockbuster potential, according to Bernstein. A late-stage trial will start in early 2026 and, if approved, the drug would be launched near the end of the decade, the analysts say. Shares rise 4.3%. (adria.calatayud@wsj.com)

0303 ET - CSPC Pharmaceutical Group's growth visibility for next year appears clouded to UOB Kay Hian analysts Carol Dou and Sunny Chen. The Chinese pharma company's nine-month finished drugs segment revenue fell 17.2% on year, compressing its gross margin significantly to 65.6% compared with 70.5% in the same period a year ago, they say in a note. While the company maintains its 2026 revenue growth outlook, the analysts expect China's volume-based procurement policy for drugs to weigh on growth. Two potential out-licensing deals may also be delayed due to changing market dynamics, according to CSPC's management. UOB KH cuts its rating on CSPC to hold from buy and trims its target to HK$8.50 from HK$12.00. Shares gain 3.0% to HK$7.79. (megan.cheah@wsj.com)

1759 ET - Ramsay Health Care's 1Q update looks positive for its stock, RBC Capital Markets says. Ramsay reaffirmed the outlook for its Australian business, signaling higher earnings in FY 2026. "However the 1Q performance of the Australian business is exceeding consensus revenue and Ebit growth expectations," analyst Craig Wong-Pan says. Ramsay said revenue from its Australian operations was up 6.5% in 1Q, driven by its private hospitals. Ebit growth of 5.8% was achieved in the quarter. "We expect today's update on the Australian business to be taken well by the market," RBC says. It has a sector perform call on Ramsay. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

November 25, 2025 12:20 ET (17:20 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.